ArticleNeuro-oncology2022
Deuterium magnetic resonance spectroscopy enables noninvasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas.
Article in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Advances and prospects in deuterium metabolic imaging (DMI): a systematic review of in vivo studies.European radiology experimental · 2024Pooled it
- High-spatiotemporal resolution deuterium metabolic imaging enables in vivo phenotyping of intra- and intertumoral heterogeneity.Science advances · 2026Article
- 1p/19q codeletion induces targetable and imageable vulnerabilities in glucose metabolism in oligodendrogliomas.Neuro-oncology · 2026Article
- Absolute Quantification of Brain Deuterium Metabolic Imaging in Healthy Volunteers and Glioblastoma Patients at 7T.Magnetic resonance in medicine · 2026Article
- Application of magnetic resonance spectroscopy (MRS) in photo-thermal therapy response of U87-MG human glioma cells with gold-coated iron oxide nanoparticles: an in vivo study.Magma (New York, N.Y.) · 2026Article
- Lactylation fuels nucleotide biosynthesis and facilitates deuterium metabolic imaging of tumor proliferation in preclinical models of H3K27M-mutant gliomas.Science translational medicine · 2026Article
- Validation of Dynamic Deuterium Metabolic Imaging (DMI) for the Measurement of Cerebral Metabolic Rates of Glucose in Rat.NMR in biomedicine · 2026Article
- Oral intake of deuterated choline at clinical dose for metabolic imaging of brain tumors.Npj imaging · 2025Article
- Support vector machine-based preoperative identification of IDH-Mutant low-grade gliomas in adult gliomas using clinical features.BMC neurology · 2025Article
- Deuterium Metabolic Imaging Enables the Tracing of Substrate Fluxes Through the Tricarboxylic Acid Cycle in the Liver.NMR in biomedicine · 2025Article
- The Role of Glia Telomere Dysfunction in the Pathogenesis of Central Nervous System Diseases.Molecular neurobiology · 2024Review
- Repeatability of deuterium metabolic imaging of healthy volunteers at 3 T.European radiology experimental · 2024Observational
- A proton birdcage coil integrated with interchangeable single loops for multi-nuclear MRI/MRS.Journal of Zhejiang University. Science. B · 2024Article
- Deuterium Magnetic Resonance Spectroscopy Quantifies Tumor Fraction in a Mouse Model of a Mixed Radiation Necrosis / GL261-Glioblastoma Lesion.Molecular imaging and biology · 2024Article
- Subcutaneous deuterated substrate administration in mice: An alternative to tail vein infusion.Magnetic resonance in medicine · 2024Article
- Deuterium metabolic imaging for 3D mapping of glucose metabolism in humans with central nervous system lesions at 3T.Magnetic resonance in medicine · 2024Article
- Current state of pediatric neuro-oncology imaging, challenges and future directions.Neoplasia (New York, N.Y.) · 2023Review
- Application and development of Deuterium Metabolic Imaging in tumor glucose metabolism: visualization of different metabolic pathways.Frontiers in oncology · 2023Review
- Deuterium Metabolic Imaging Reports on TERT Expression and Early Response to Therapy in Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe alternative lengthening of telomeres (ALT) pathway is essential for tumor proliferation in astrocytomas. The goal of this study was to identify metabolic alterations linked to the ALT pathway that can be exploited for noninvasive magnetic resonance spectroscopy (MRS)-based imaging of astrocytomas in vivo.
methodsGenetic and pharmacological methods were used to dissect the association between the ALT pathway and glucose metabolism in genetically engineered and patient-derived astrocytoma models. 2H-MRS was used for noninvasive imaging of ALT-linked modulation of glycolytic flux in mice bearing orthotopic astrocytomas in vivo.
resultsThe ALT pathway was associated with higher activity of the rate-limiting glycolytic enzyme phosphofructokinase-1 and concomitantly elevated flux of glucose to lactate in astrocytoma cells. Silencing the ALT pathway or treating with the poly(ADP-ribose) polymerase inhibitor niraparib that induces telomeric fusion in ALT-dependent astrocytoma cells abrogated glycolytic flux. Importantly, this metabolic reprogramming could be non-invasively visualized by 2H-MRS. Lactate production from [6,6'-2H]-glucose was higher in ALT-dependent astrocytoma tumors relative to the normal brain in vivo. Furthermore, treatment of orthotopic astrocytoma-bearing mice with niraparib reduced lactate production from [6,6'-2H]-glucose at early timepoints when alterations in tumor volume could not be detected by anatomical imaging, pointing to the ability of [6,6'-2H]-glucose to report on pseudoprogression in vivo.
conclusionsWe have mechanistically linked the ALT pathway to elevated glycolytic flux and demonstrated the ability of [6,6'-2H]-glucose to non-invasively assess tumor burden and response to therapy in astrocytomas. Our findings point to a novel, clinically translatable method for metabolic imaging of astrocytoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.